|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
SELECT PUBLICATIONS Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract Bria E et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006;106(11):2337-44. Abstract Burstein HJ et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23(33):8340-7. Abstract Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract Duric VM et al. Patients’ preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 2005;16(11):1786-94. Abstract
Eiermann W et al. Phase III randomized trial comparing docetaxel in combination with
doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide
followed by docetaxel (AC
Goldstein L et al. E2197: Phase III AT (doxorubicin/docetaxel) vs AC (doxorubicin/ Harlan LC et al. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 2006;24(6):872-7. Abstract Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41. Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40. Kummel S et al. Randomised trial: Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 2006;94(9):1237-44. Abstract Kuru B et al. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer Res 2005;24(3):363-72. Abstract Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Canc Netw 2005;3(4):557-71. Abstract Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract Martin M et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: Interim efficacy analysis of GEICAM 9906 Trial. San Antonio Breast Cancer Symposium 2005b;Abstract 39. Roche H et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 27. Vogel CL et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178-84. Abstract
|
|
 |
Terms of Use/Disclaimer | Privacy Policy | Hardware/Software Requirements Copyright © 2006 Research To Practice. All Rights Reserved |
 |
T) in Her-2/neu negative early breast cancer patients with
positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. San Antonio
Breast Cancer Symposium 2005;
